A perovskite quantum dot and a method and application of synthesizing the perovskite quantum dot in aqueous solution
By using longer chain ligand compounds to react with halogen groups-containing lead and cesium sources under mild conditions, the problems of CsPbX3 quantum dot stability and industrial production were solved, and high stability and simplified synthesis perovskites were achieved. Quantum dots, suitable for use in aqueous solutions.
Patent Information
- Application Number
- CN202310622663.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-05-29
AI Technical Summary
CsPbX3 quantum dots are sensitive to the environment and have poor stability. The existing coating methods are difficult to effectively improve light stability and industrial production conditions, and the quantum dots prepared in aqueous solutions are poorly stable.
Using two longer chain ligand compounds to react with halogen groups-containing lead and cesium sources, perovskite quantum dots are synthesized under mild conditions through simple raw material mixing methods, enhancing their stability and steric position in water. Resistance effect.
The preparation of perovskite quantum dots with high stability is achieved, simplifies the synthesis process, is suitable for industrial production, and maintains stability and photoelectric properties in aqueous solution for a long time.
Smart Images

Figure HDA0004259653010000011 
Figure HDA0004259653010000012 
Figure HDA0004259653010000021
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of perovskite, and in particular to a perovskite quantum dot and a method and application of synthesizing the perovskite quantum dot in an aqueous solution. Background Art
[0002] All-inorganic perovskite CsPbX 3 (X=Cl, Br, I) quantum dots (PQDs) have broad application prospects in display and photodetector fields due to their excellent optoelectronic properties and low cost. 3 PQDs are sensitive to the environment and are easily affected by light, heat, water, and oxygen, which is not conducive to practical applications. There are many solutions to improve the stability of CsPbX3 PQDs, but there are also some shortcomings. For example, some polymers or inorganic materials are used to coat quantum dots to improve their stability, but some polymer materials are difficult to prevent the diffusion of oxygen, and the resulting composite materials often have poor light stability. The synthesis temperature of inorganic materials is relatively high and the synthesis conditions are relatively complex. At present, most of the inorganic coating dots use some porous inorganic materials. However, the presence of these holes will cause some quantum dots to be exposed to the environment; others use other ions to dope perovskites to improve stability to a certain extent, but it will affect CsPbX 3 Intrinsic emission of PQDs.
[0003] At present, most of the preparation methods of quantum dots are synthesized by high temperature hot injection. For example, under high temperature inert conditions (140-200℃), cesium oleylamine is quickly injected into a certain amount of PbX 2 , oleylamine, and a mixed solution of oleylamine and octadecene. After reacting for a few seconds, transfer to ice water for cooling, and then collect the sample after centrifugal purification. However, the synthesis steps of this method are relatively complicated and need to be carried out under anhydrous, oxygen-free and high temperature conditions, which is not conducive to industrial production. In addition, this method uses room temperature supersaturated crystallization to prepare CsPbX3 PQDs, which requires the use of organic solvents such as toluene, and the generated quantum dots have poor water stability. There are also literature reports on methods for preparing synthetic perovskite quantum dots in aqueous solutions, but the stability of the generated quantum dots is poor and cannot be stored and used for a long time.
[0004] Based on this, a new type of CsPbX with high stability is urgently needed. 3 PQDs and preparation of the above CsPbX 3 PQDs are used to solve the above problems. Summary of the invention
[0005] The first technical problem to be solved by the present invention is:
[0006] A perovskite quantum dot is provided.
[0007] The second technical problem to be solved by the present invention is:
[0008] Provided is a method for preparing the perovskite quantum dots.
[0009] The third technical problem to be solved by the present invention is:
[0010] Applications of the perovskite quantum dots.
[0011] In order to solve the first technical problem, the technical solution adopted by the present invention is:
[0012] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0013] Lead sources containing halogen groups;
[0014] A cesium source containing a halogen group;
[0015] a first ligand compound;
[0016] a second ligand compound;
[0017] The number of carbon atoms of the first ligand compound is 6-10;
[0018] The second ligand compound has 18 or more carbon atoms.
[0019] According to the embodiments of the present invention, one of the technical solutions has at least one of the following advantages or beneficial effects:
[0020] The perovskite quantum dots of the present invention use two relatively long-chain ligand compounds to enhance the binding force with the surface of the quantum dots and enhance the steric hindrance effect, so that the quantum dots can be more stably dispersed in water. In addition, the use of two relatively long-chain ligand compounds combined with the quantum dots can better inhibit the erosion of water molecules, ensure that the structure of the quantum dots is not destroyed, and further improve its stability.
[0021] According to one embodiment of the present invention, the molar ratio of the lead source containing halogen groups to the cesium source containing halogen groups is 0.4-1:0.4-2.
[0022] The molar ratio of the first ligand compound to the second ligand compound is 1.5-2.5 mmol:1.5-2.5 mmol.
[0023] According to one embodiment of the present invention, the dosage of the first ligand compound is 1.5-2.5 mmol.
[0024] According to one embodiment of the present invention, the halogen group is -Cl, -Br or -I.
[0025] According to one embodiment of the present invention, the first ligand compound includes at least one of 6-bromohexanoic acid, 8-bromooctanoic acid and 10-bromodecanoic acid. The first ligand compound can coordinate with the quantum dots to varying degrees, such as the Br at the end of the 10-bromodecanoic acid ligand. - Can be combined with Pb in quantum dots 2+ Coordination prevents the quantum dots from being destroyed in aqueous solution and enables them to be more stably dispersed in the aqueous solution.
[0026] According to one embodiment of the present invention, the carbon number of the second ligand compound is equal to 18, and the second ligand compound includes oleylamine. The oleylamine ligand can promote the formation of quantum dot crystal nuclei.
[0027] In order to solve the second technical problem, the technical solution adopted by the present invention is:
[0028] A method for preparing the perovskite quantum dots comprises the following steps:
[0029] S1: mixing a lead source containing a halogen group and a cesium source containing a halogen group in a solvent;
[0030] S2: adding the first ligand compound and the second ligand compound into the mixed solution to obtain perovskite quantum dots.
[0031] According to the embodiments of the present invention, one of the technical solutions has at least one of the following advantages or beneficial effects:
[0032] The method for preparing the perovskite quantum dots of the present invention avoids the use of the traditional hot injection method of high temperature, anhydrous and oxygen-free, simplifies the experimental preparation method, and can synthesize highly stable perovskite quantum dots only by simple mixing of raw materials. The method of the present invention has the characteristics of simple and efficient synthesis and can be used for industrial production.
[0033] According to one embodiment of the present invention, the solvent comprises dimethylacetamide.
[0034] According to one embodiment of the present invention, in steps S1 and S2, the temperature is 40-100°C.
[0035] According to one embodiment of the present invention, step S1 further includes the following steps: after mixing the lead source containing a halogen group and the cesium source containing a halogen group with a solvent, stirring at a rotation speed of 500-1000 rpm / min.
[0036] Another aspect of the present invention provides a photodetector comprising the aforementioned perovskite quantum dot.
[0037] Other features and advantages of the present invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0039] Figure 1 This is the X-ray diffraction test diagram of the perovskite quantum dots prepared in Example 1.
[0040] Figure 2 This is an electron microscope test image of the perovskite quantum dots prepared in Example 1.
[0041] Figure 3 This is a test graph of the quantum dot excitation spectrum of the perovskite quantum dots prepared in Example 1.
[0042] Figure 4 This is a 7-day stability test chart of the perovskite quantum dots prepared in Example 1 and Example 10.
[0043] Figure 5 This is a 38-day stability test chart of the perovskite quantum dots prepared in Example 1. DETAILED DESCRIPTION
[0044] The embodiments of the present invention are described in detail below, and the same or similar reference numerals throughout the embodiments represent the same or similar elements or elements with the same or similar functions. The embodiments described below are exemplary and are only used to explain the present invention, and cannot be understood as limiting the present invention.
[0045] In the description of the present invention, if there is a description of first, second, etc., it is only for the purpose of distinguishing technical features, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features or implicitly indicating the order of the indicated technical features.
[0046] The words "preferably", "more preferably", etc. in the present invention refer to embodiments of the present invention that may provide certain beneficial effects in certain circumstances. However, other embodiments may also be preferred under the same circumstances or other circumstances. In addition, the description of one or more preferred embodiments does not imply that other embodiments are not applicable, nor is it intended to exclude other embodiments from the scope of the present invention.
[0047] When a numerical range is disclosed herein, the above range is considered to be continuous and includes the minimum and maximum values of the range, as well as every value between such minimum and maximum values. Further, when a range refers to an integer, every integer between the minimum and maximum values of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be combined. In other words, unless otherwise indicated, all ranges disclosed herein should be understood to include any and all subranges included therein.
[0048] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of the present invention.
[0049] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0050] Example 1
[0051] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0052] PbB 2 ;
[0053] CsBr;
[0054] 10-bromodecanoic acid;
[0055] Oleylamine.
[0056] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0057] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0058] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0059] S3: Add 2 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0060] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0061] Example 2
[0062] The difference between this example and Example 1 is that: PbBr in (S2) 2 The dissolution temperature with CsBr is 40°C.
[0063] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0064] PbB 2 ;
[0065] CsBr;
[0066] 10-bromodecanoic acid;
[0067] Oleylamine.
[0068] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0069] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0070] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 40°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0071] S3: Add 2 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0072] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0073] Example 3
[0074] The difference between this example and Example 1 is that PbBr in (S2) 2 The dissolution temperature with CsBr is 80℃.
[0075] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0076] PbB 2 ;
[0077] CsBr;
[0078] 10-bromodecanoic acid;
[0079] Oleylamine.
[0080] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0081] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0082] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 80 °C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0083] S3: Add 2 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0084] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0085] Example 4
[0086] The difference between this example and Example 1 is that PbBr in (S2) 2 The dissolution temperature with CsBr is 100°C.
[0087] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0088] PbB 2 ;
[0089] CsBr;
[0090] 10-bromodecanoic acid;
[0091] Oleylamine.
[0092] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0093] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0094] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 100 °C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0095] S3: Add 2 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0096] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0097] Example 5
[0098] The difference between this example and Example 1 is that the amount of 10-bromodecanoic acid used in (S3) is 1.5 mmol.
[0099] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0100] PbB 2 ;
[0101] CsBr;
[0102] 10-bromodecanoic acid;
[0103] Oleylamine.
[0104] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0105] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0106] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0107] S3: Add 1.5 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0108] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0109] Example 6
[0110] The difference between this example and Example 1 is that the amount of 10-bromodecanoic acid used in (S3) is 2.5 mmol.
[0111] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0112] PbB 2 ;
[0113] CsBr;
[0114] 10-bromodecanoic acid;
[0115] Oleylamine.
[0116] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0117] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0118] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0119] S3: Add 2.5 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0120] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0121] Example 7
[0122] The difference between this example and Example 1 is that the amount of oleylamine used in (S3) is 1.5 mmol.
[0123] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0124] PbB 2 ;
[0125] CsBr;
[0126] 10-bromodecanoic acid;
[0127] Oleylamine.
[0128] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0129] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0130] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0131] S3: Add 2 mmol of 10-bromodecanoic acid and 1.5 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0132] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0133] Example 8
[0134] The difference between this example and Example 1 is that the amount of 10-bromodecanoic acid used in (S3) is 2.5 mmol.
[0135] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0136] PbB 2 ;
[0137] CsBr;
[0138] 10-bromodecanoic acid;
[0139] Oleylamine.
[0140] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0141] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0142] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0143] S3: Add 2.5 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0144] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0145] Example 9
[0146] The difference between this example and Example 1 is that 10-bromodecanoic acid in (S3) is replaced by 6-bromohexanoic acid.
[0147] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0148] PbB 2 ;
[0149] CsBr;
[0150] 6-bromohexanoic acid;
[0151] Oleylamine.
[0152] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0153] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0154] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0155] S3: Add 2 mmol of 6-bromohexanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0156] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0157] Example 10
[0158] The difference between this example and Example 1 is that 10-bromodecanoic acid in (S3) is replaced by 8-bromooctanoic acid.
[0159] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0160] PbB 2 ;
[0161] CsBr;
[0162] 8-Bromooctanoic acid;
[0163] Oleylamine.
[0164] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0165] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0166] S2 weighed 0.4 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0167] S3: Add 2 mmol of 8-bromooctanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0168] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0169] Embodiment 11
[0170] The difference between this example and Example 1 is that PbBr in (S2) 2 Change to PbI 2 , change CsBr to CsI.
[0171] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0172] PbI 2 ;
[0173] CsI;
[0174] 10-bromodecanoic acid;
[0175] Oleylamine.
[0176] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0177] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0178] S2 weighed 0.4 mmol of PbI 2 and 0.4 mmol of CsI were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0179] S3: Add 2 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0180] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0181] Example 12
[0182] The difference between Example 12 and Example 1 is that PbBr 2 The dosage of PbBr in Example 12 is different. 2 The dosage is 1 mmol.
[0183] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0184] PbB 2 ;
[0185] CsBr;
[0186] 10-bromodecanoic acid;
[0187] Oleylamine.
[0188] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0189] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0190] S2 weighed 1 mmol of PbBr 2 and 0.4 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0191] S3: Add 2 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0192] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0193] Embodiment 13
[0194] The difference between Example 13 and Example 1 is that the amount of CsBr used is different. The amount of CsBr used in Example 12 is 1 mmol.
[0195] A perovskite quantum dot, wherein the raw materials for preparing the perovskite quantum dot include the following components:
[0196] PbB 2 ;
[0197] CsBr;
[0198] 10-bromodecanoic acid;
[0199] Oleylamine.
[0200] The preparation of the above-mentioned perovskite quantum dots comprises the following steps:
[0201] S1 Measure 10 ml of dimethylacetamide (DMA) solution and place it in a 30 ml glass bottle;
[0202] S2 weighed 0.4 mmol of PbBr 2 and 1 mmol of CsBr were poured into the glass bottle containing DMA, placed in an oil bath at 60°C and stirred at 500 rpm / min for 35 min to fully dissolve;
[0203] S3: Add 2 mmol of 10-bromodecanoic acid and 2 mmol of oleylamine to the above solution respectively, and continue stirring for 15 min to obtain a mixed solution;
[0204] S4: 1 ml of the mixed solution was added into 10 ml of deionized water, and the mixture was stirred for 10 min before collecting the sample to obtain perovskite quantum dots.
[0205] Performance Test:
[0206] The perovskite quantum dots prepared in Example 1 were subjected to an X-ray diffraction test, and the test results are as follows: Figure 1 As shown, Figure 1 Where 2Theta is the diffraction angle and Intensity is the intensity.
[0207] from Figure 1 It can be seen that the three obvious diffraction peaks of the sample are 15.2°, 21.5°, and 30.6°, corresponding to the (1 00), (1 1 0), and (2 0 0) crystal planes, respectively. Its characteristic peaks match well with the standard card (JCPDS#54-0752), confirming that the cubic perovskite structure of CsPbBr was synthesized. 3 PQDs.
[0208] The perovskite quantum dots prepared in Example 1 were tested by electron microscope. The test results are as follows: Figure 2 .in, Figure 2 (a) is the transmission electron microscope (TEM) test, Figure 2 (b) is a high-resolution transmission electron microscopy (HR-TEM) test. Figure 2 In (a), it can be seen that CsPbBr is clearly dispersed. 3 PQD, size distribution is 15-25nm, from Figure 2 (b) The high-resolution TEM (HR-TEM) in the figure shows obvious uniform lattice fringes, and the distance between the lattice planes is about 0.142nm. Compared with the standard card, it can be seen that it belongs to the (1 1 0) crystal plane of the cubic phase CsPbBr3.
[0209] The perovskite quantum dots prepared in Example 1 were tested for quantum dot excitation spectrum. The test results are as follows: Figure 3 As shown, Figure 3 In the equation, Wavelength is the wavelength and Intensity is the intensity. Figure 3 It can be seen that the sample exhibits bright green emission under 370nm excitation with a half-width (FWHM) of 16.5nm. When monitoring the green emission at 524nm, the excitation spectrum contains a broadband peak from 300-480nm, indicating that this composite material can be effectively excited by UV or blue LED chips.
[0210] The perovskite quantum dots prepared in Example 1 and Example 10 were subjected to a 7-day stability test. The test results are as follows: Figure 4 As shown, Figure 4 In the above table, Time is the time and PL Intensity is the light intensity. Figure 4 It can be seen that the longer-chain 10-bromodecanoic acid ligand showed better stability under the monitoring of 0-7 days, indicating that the longer-chain ligand has better ability to inhibit the hydrolysis of quantum dots in aqueous solution.
[0211] The perovskite quantum dots prepared in Example 1 were subjected to a 38-day stability test. The test results are as follows: Figure 5 As shown, Figure 5 In the equation, Wavelength is the wavelength and Intensity is the intensity. Figure 5 It can be seen from the figure that the sample still has strong emission performance after 38 days. Figure 4 It can also be seen from the stability comparison data that because the perovskite quantum dots in Example 1 use two longer-chain ligand compounds to enhance the steric hindrance effect, after the ligand compounds are combined with the surface of the quantum dots, the stability of the quantum dots in aqueous solution is greatly improved. Conversely, since the stability test results show that the stability is improved, it can be further inferred that the two longer-chain ligand compounds have extremely strong binding force with the quantum dots and promote the enhancement of the steric hindrance effect.
[0212] The results of Examples 2-13 are similar to those of Example 1 and are not shown one by one to avoid redundancy.
[0213] The above are only embodiments of the present invention, and are not intended to limit the patent scope of the present invention. Any equivalent transformations made using the contents of the present invention specification, or directly or indirectly applied in related technical fields, are also included in the patent protection scope of the present invention.
Claims
1. A perovskite quantum dot, characterized in that: The raw materials for preparing the perovskite quantum dots include the following components: Lead sources containing halogen groups; A cesium source containing a halogen group; a first ligand compound; a second ligand compound; The first ligand compound is at least one of 6-bromohexanoic acid, 8-bromooctanoic acid and 10-bromodecanoic acid; The second ligand compound is oleylamine; The method for preparing the perovskite quantum dots comprises the following steps: S1: mixing a lead source containing a halogen group and a cesium source containing a halogen group in a solvent to obtain a mixed solution; S2 adding the first ligand compound and the second ligand compound to the mixed solution to obtain perovskite quantum dots; In the steps S1 and S2, the temperature is 40-100°C; The halogen group is -Br or -I.
2. A perovskite quantum dot according to claim 1, characterized in that: The molar ratio of the lead source containing halogen groups to the cesium source containing halogen groups is 0.4-1:0.4-2.
3. A perovskite quantum dot according to claim 1, characterized in that: The molar ratio of the first ligand compound to the second ligand compound is 1.5-2.5 mmol:1.5-2.5 mmol.
4. The perovskite quantum dot according to claim 1, characterized in that: The solvent includes dimethylacetamide.
5. A photoelectric detector, characterized in that: A perovskite quantum dot comprising any one of claims 1 to 4.
